Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164988 | 0.96 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10HPGDGFER | |
| SCHEMBL22289913 | 0.87 | GFER (0.46) | KDM4EALDH1A1HSD17B10HPGDGFER | |
| SCHEMBL7454498 | 0.78 | CFTR (0.56) | KDM4EALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL2392492 | 0.77 | KDM4E (0.60) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3429404 | 0.76 | PTK2 (0.44) | KDM4EALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL6952749 | 0.75 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10HPGDGFER | |
| SCHEMBL6162507 | 0.75 | ADORA2A (0.55) | ALDH1A1HPGDKMT2ATSHRPOLB | |
| SCHEMBL7679755 | 0.75 | CFTR (0.56) | KDM4EALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL4789593 | 0.74 | HSD17B10 (0.47) | KDM4EALDH1A1HSD17B10HPGDGFER | |
| SCHEMBL6162671 | 0.74 | HPGD (0.55) | ALDH1A1HPGDKMT2ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
| EP-1056724-B1 | SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6448259-B1 | CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-6194427-B1 | BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS | NEUROGEN CORPORATION | 2001-02-27 | — | — | US | disclosed |
| EP-1056724-A2 | SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043661-A2 | SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | KDM4E 979/4885ALDH1A1 1675/4885HSD17B10 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.